# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price ta...
https://www.axios.com/pro/biotech-deals/2025/10/10/cero-therapeutics-ceo-open-takeover-offers
https://register.epo.org/application?number=EP22758100
D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price ta...
Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional resul...
D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price ta...
Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering t...